Skip to main content

Drug Discovery Mitochondrial Toxicology

De-Risk Your Drug Discovery Pipeline | Assessing mitochondrial toxicities and liabilities
Don't let mitochondrial‐toxic compounds slip through

Identifying compounds that induce toxicities is an important part of lead‐optimization during drug discovery. However, most commonly used end‐point assays lack the sensitivity to capture many compounds with mitochondrial toxicity, leading to late‐stage failures.

Agilent cell analysis solutions provide real‐time, direct measurements of mitochondrial metabolism with the highest specificity and sensitivity. With these solutions, you can be confident the data you're collecting provides an accurate picture of mitochondrial toxicity risk enabling you to make informed decisions on your drug development pipeline.

No matter your workflow, we have the solution
  • Screening Screening
  • Investigative Investigative
  • Predictive Predictive
  • Mechanistic Mechanistic

Often the initial step in mitochondrial toxicology studies is to screen your compound library to identify any compounds with potential mitochondrial toxicity. With the Agilent MitoXpress Xtra oxygen consumption assay, you can screen your library using a direct measure of mitochondrial metabolism in a high‐throughput 384‐well format. See how

Evaluating mitochondrial toxicity prediction using in vitro assays and mechanistic determination

View our on-demand webinar to learn how researchers from Cyprotex leverage a number of in vitro approaches to detect compounds which can result in mitochondrial toxicity.

Webinar
Agilent metabolic measurement solutions

Enhance your drug discovery workflow with live cell, real‐time metabolic analysis solutions from Agilent. Learn more about our solutions.

For Research Use Only. Not for use in diagnostic procedures.